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Retroviral insertional mutagenesis in mice is considered a power-
ful forward genetic strategy to identify disease genes involved in
cancer. Our high-throughput screens led to frequent identifica-
tion of the genes encoding the enzymes engaged in histone
lysine methylation. Histone methylation can positively or nega-
tively impact on gene transcription, and then fulfill important
roles in developmental control and cell-fate decisions. A tremen-
dous amount of progress has accelerated the characterization of
histone methylations and the enzymes that regulate them.
Deregulation of these histone methyl-modifying enzymes has
been increasingly recognized as a hallmark of cancer in the last
few years. However, in most cases, we have only limited under-
standing for the molecular mechanisms by which these enzymes
contribute to cancer development and progression. In this
review, we summarize the current knowledge regarding some of
the best-validated examples of histone lysine methyltransferases
and demethylases associated with oncogenesis and discuss
their potential mechanisms of action. (Cancer Sci 2013; 104: 795–
800)
A great body of evidence supports that epigenetic changesare responsible for cancer development.(1,2) There are
different types of mechanisms in the field of epigenetics: DNA
methylation, post-translational modifications of histones, chro-
matin remodeling and noncoding RNAs. The earliest demon-
stration of an epigenetic link to cancer was derived from the
studies about DNA methylation. Evidence showing the role of
DNA hyper- or hypo-methylation in oncogenesis has been accu-
mulating for more than 20 years. However, the role of the other
mechanisms is an emerging area of interest. During the past
decade, the focus has shifted to studies of post-translational
modifications of histones, because alterations in the balance of
histone modifications lead to deregulated gene expression and
are associated with cancer. The nucleosome, the basic building
block of chromatin, is composed of two copies of each histone:
H2A, H2B, H3, and H4. The amino-terminal tails of histones are
subject to posttranslational modifications (Fig. 1a), which
include acetylation, methylation, phosphorylation, ubiquitylation
and SUMOylation. These modifications influence the structure
of chromatin and show different functional outputs depending
on the type, the site and the degree of modifications. The modifi-
cation pattern of histone has been linked to gene function during
development and tumorigenesis.
Identification of genes involved in cancer gives us crucial
information about the molecular mechanism of cancer develop-
ment. Genetic screens for mutations contributing to tumor
formation in model organisms facilitate the efficient identifica-
tion of cancer genes in an in vivo setting. Retroviral insertional
mutagenesis in mice is one of the potent cancer gene discovery
tools.(3) Previously we have accomplished high-throughput
cloning of retroviral integration sites from the tumors of
murine leukemia virus (MuLV)-infected mice.(4) This led to
the identification of hundreds of candidate cancer genes includ-
ing many genes encoding histone lysine methyltransferases
(KMTs) and demethylases (KDMs). In this review, we discuss
the current state of knowledge regarding histone lysine methyl-
ation and especially highlight new insights into the role of
KDMs in the course of cancer development.
Frequent Identification of Histone-Modifying Enzymes by
Retroviral Insertional Mutagenesis
Slow transforming retroviruses such as MuLV can efficiently
induce tumors in mice by integrating into host genome and
deregulating the expression of proto-oncogenes or inactivating
the expression of tumor suppressor genes (Fig. 1b).(3) Thus the
retroviral integration sites in the tumors provide powerful
molecular tags for cancer gene discovery. The ability to find
oncogenic mutations has been accelerated by technical advances
including PCR-based cloning of retroviral integration sites, the
availability of mouse genome sequence, and high-throughput
DNA sequencing.(5) Many of the identified mutations in these
screens are not restricted to the tumor formation in mice, but
also play a causal role in the development of human cancers.(5)
High-throughput retroviral tagging allowed identification of
novel cancer-inducing loci involved in the development of
particular types of tumors, or that collaborate with known
oncogenic pathways.(4,6–8) We have established the Retroviral
Tagged Cancer Gene Database (RTCGD, http://variation.osu.
edu/rtcgd/) containing a collection of retroviral insertional
screens.(9) The RTCGD creates the opportunity for multiple
datasets to be compared and is periodically updated with the
supply of recently reported retroviral integration sites. During
our high-throughput screens, many genes encoding KMTs and
KDMs (Fig. 1c, as indicated with red letters) have been identi-
fied as potential oncogenes or tumor suppressor genes.(4,8) The
result provided us the opportunity to explore the functions of
these enzymes in tumor initiation and progression.
Histone Modifications in Cancer
Historically, histone acetylation is the most extensively studied
modification on histone amino-terminal tails.(10) Acetylation of
lysine residues on histone H3 and H4 leads to the formation of
an open chromatin structure, which induces transcriptional
activation. Acetylation is regulated by the competing activities
of two enzyme families, histone lysine acetyltransferases
(HATs) and deacetylases (HDACs). Mutations or chromosomal
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translocations of HAT genes including Gcn5 ⁄PCAF, p300
⁄CBP and the MYST families are detected in various solid
tumors and hematological cancers.(10) On the other hand,
HDAC overexpression is frequently observed in various can-
cers.(11) Histone lysine deacetylases are implicated in cancer
due to their aberrant transcriptional silencing of tumor suppres-
sor genes. As a result, the enzymatic inhibitors of HDACs
have been developed as anti-cancer drugs.(12)
In contrast, histone methylation had been thought to be an
irreversible process for a long time. The discovery of KMTs and
KDMs has resulted in a completely different view of histone
methylation in which this modification is dynamic.(13,14) Revers-
ible histone lysine methylation is implicated in diverse biologi-
cal processes including cellular proliferation, differentiation,
DNA repair and recombination.(13) The importance of the tight
regulation of histone methylation is indicated by emerging links
of histone methylation to human disease such as cancer.(15,16)
Regulation of Histone Lysine Methylation
Histone lysine methylation is associated with activated or
repressed transcription of individual genes depending on the
residue and the degree, since lysine residues can be mono-,
di- or tri-methylated (me1, me2 or me3).(14) Moreover, a given
methylated mark is often linked to a specific position of the
gene, either around the transcription start site (TSS) or in the
coding region, regulating transcriptional initiation or elonga-
tion. In general, methylation of lysine-4 of histone H3 (H3K4)
around TSS and methylation of H3K36 and H3K79 on the
coding region are associated with active transcription.(17)
Methylation of H3K9 and H3K27 on promoters correlates with
transcriptional repression.(17)
A large number of KMTs and KDMs have been identified so
far (Fig. 2). Two classes of KMTs, the SET domain-containing
enzymes and the DOT1-like proteins, have been shown to
methylate specific lysine residues of histones.(16) Similarly, two
families of KDMs have been identified, the flavin adenine dinu-
cleotide (FAD)-dependent amine oxidases (LSD1 ⁄KDM1A)
and the Jumonji C (JmjC) domain-containing demethylases that
are Fe (II) and a-ketoglutarate-dependent enzymes. KDMs also
have exquisite substrate specificity.(13,14)
KMTs in Cancer
The roles of KMTs in cancer have been extensively reviewed(18);
therefore, in this review, we will focus on EZH2 ⁄KMT6 methyl-
transferase, since it is often found as a key player in human malig-
nancies.(18) EZH2 is the catalytic component of the polycomb
repressor complex 2 (PRC2), which is primarily responsible for
H3K27 methylation. Gene-expression studies demonstrated EZH2
upregulation in a number of tumors such as prostate, breast, lung
and colon cancer.(18) Downregulation of microRNA-101, a nega-
tive regulator of EZH2, has been also reported as a cause of
EZH2 overexpression in prostate cancer.(19) In B cell lymphoma,
gain-of-function mutations in EZH2 have been discovered, sup-
porting the notion that EZH2 is an oncogene.(20) Importantly,
EZH2-mediated tri-methylation of H3K27 was proposed as a
mechanism of tumor-suppressor gene silencing in cancer that is
independent of promoter DNA methylation.(21) In addition, over-
expression of EZH2 frequently correlates with advanced cancer
and poor prognosis.(22) However, deep-sequencing projects of
cancer genomes have recently identified coding mutations within
EZH2 in various myeloid and lymphoid neoplasms, suggesting a




Fig. 1. Retroviral insertional mutagenesis demonstrated the involvement of histone-modifying enzymes in cancer development. (a) Histone
modifications. Chromatin is the macromolecular complex of DNA and histone proteins, and the basic unit of chromatin is the nucleosome. It con-
tains a histone octamer, with two each of histones H2A, H2B, H3 and H4. The amino-terminal tails of histones are subject to posttranslational
modifications including acetylation, methylation and phosphorylation, which play a critical role in the regulation of DNA-based biological
processes. (b) Retroviral insertional mutagenesis. Retroviruses induce tumors by randomly integrating into the host genome. The mechanism
leading to cancer is thought to be the activation of proto-oncogenes or inactivation of tumor suppressor genes. (c) Histone modifying enzymes
identified by retroviral tagging. Using high-throughput analysis, we found many genes encoding histone methyltransferases and demethylases
(indicated with red letters) as potential oncogenes or tumor suppressor genes. Histone acetylation has been unambiguously associated with
cancer, but the importance of histone methylation in cancer is just beginning to be uncovered.
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KDMs in Cancer
Recent studies provide increasing genetic evidence suggesting
that mutation or deregulation of KDMs may be a critical deter-
minant in cancer development. This has been described in
several reviews,(15,16,24) and we will therefore limit the discus-
sion here to some key examples. Table 1 provides an overview
for KDMs and their association with human cancer.
LSD1 ⁄KDM1A. LSD1 ⁄KDM1A is the first protein reported to
possess histone demethylase activity in mammalian cells.
Especially, there is a growing interest in LSD1 as a potential
target for cancer therapies.(25) Expression levels of LSD1 are
significantly elevated in prostate, bladder, lung, colorectal
cancer and neuroblastoma.(26–28) Knockdown or chemical
inhibition of LSD1 was shown to inhibit the proliferation of
several cancer cell lines that overexpress LSD1.(25,27) LSD1
was reported to regulate the expression of genes involved in
chromatin regulations such as chromatin remodeling and
assembly, thereby contributing to oncogenesis.(27) However, a
recent paper demonstrated that overexpression of LSD1 in cer-
tain breast cancers suppressed metastasis and reduced tumor
growth.(29) These results suggest that the role of LSD1 in
tumorigenesis is significantly dependent on its cellular con-
text.
KDM6 family. Just as EZH2 H3K27 methyltransferase is
found aberrant in many cancers, H3K27 demethylases are
mutated and deregulated. There are two histone demethylases,
UTX ⁄KDM6A and JMJD3 ⁄KDM6B, specific for H3K27me3 ⁄
me2.(30) Inactivating mutations in the UTX gene were the first
cancer-associated mutations identified in the KDM family and
have been found in many cancers such as multiple myeloma,
esophageal squamous cell carcinoma, renal cell carcinoma and
myelomonocytic leukemia.(31–33) The expression of JMJD3 was
also shown to be decreased in subsets of human cancers, indi-
cated by data-mining analysis using published microarray
data.(34,35) Therefore, both of the mammalian H3K27 demethy-
lases are suggested to possess tumor-suppressive characteristics.
We have identified UTX as one of the candidate tumor
suppressor genes targeted by retroviral integrations in our
screens. We first examined the effects of UTX overexpression
and found significant decrease of cell growth dependent on
intact catalytic activity.(36) The growth inhibition by UTX was
due to aberrant transcriptional activation of retinoblastoma
tumor suppressor gene RB and its related RBL2 through
Fig. 2. Dynamic regulation of histone lysine
methylation. The amino-terminal tails of the
histone H3 and four most characterized lysine
residues are shown. The methylation at lysine 4
(K4) and K36 correlates with transcriptionally
active genes, whereas methylation at K9 and K27
is linked to transcriptional repression. Histone
lysine methyltransferases (KMTs) and demethylases
(KDMs) for various lysine residues are shown in the
yellow and blue boxes, respectively.
Table 1. Connections between histone demethylases and human cancer
Name Synonyms Alteration Associated human cancer Reference
KDM1A LSD1, AOF2 Overexpression Prostate cancer, neuroblastoma, lung cancer, colorectal carcinoma and
bladder cancer
(26,27,28)
Downregulation Breast cancer (29)
KDM2B FBXL10, JHDM1B Overexpression Pancreatic ductal adenocarcinoma and various leukemia (59,60)
Downregulation Glioblastoma multiform (61)
KDM3A JMJD1A, JHDM2A Overexpression Malignant colorectal cancer and renal call carcinoma (62,63)
KDM4A JMJD2A Overexpression Lung and breast cancer (56,57)
KDM4B JMJD2B Overexpression Estrogen receptor-positive breast cancer, bladder and lung cancer (43,58)
KDM4C JMJD2C, GASC1 Amplification
Overexpression
Esophageal cancer, breast cancer, medulloblastoma, primary mediastinal
B cell and Hodgkin lymphoma
(37,39,40,41)
KDM5A JARID1A, RBP2 Overexpression Gastric cancer and breast cancer (48,49)
Translocation Acute myeloid leukemia (64)
KDM5B JARID1B, PLU1 Overexpression Breast cancer, prostate cancer and bladder and lung cancer (44,45,46,47)
Downregulation Malignant melanoma (65)
KDM6A UTX Mutation Multiple cancers including multiple myeloma, esophageal squamous cell
carcinomas, renal cell carcinomas and chronic myelomonocytic leukemia
(31,32,33)
KDM6B JMJD3 Downregulation Lung, liver carcinomas and various hematopoietic malignancies (34,35)
PHF8 JHDM1F Overexpression Prostate cancer (66)
Suzuki et al. Cancer Sci | July 2013 | vol. 104 | no. 7 | 797
© 2013 Japanese Cancer Association
H3K27 demethylation. Thus RB pathway was shown to be one
of the downstream targets of UTX-mediated cell growth
control.
Overexpression of JMJD3 similarly led to cell cycle arrest,
but JMJD3 was shown to activate the expression of INK4A-
ARF locus through its demethylase activity.(34,35) Moreover,
JMJD3 expression itself was induced by activation of the
RAS-RAF pathway, suggesting that it could be involved in
oncogene-induced senescence. Depletion of JMJD3 enabled
cells to overcome the senescence, an important barrier to
tumorigenesis. Therefore, although both UTX and JMJD3 can
antagonize EZH2 activity and switch from a repressive to an
active chromatin status, they play distinct roles in cancer
development by regulating different target genes.
KDM4 family. Interestingly, oncogenic potential of the genes
in the KDM family was described long before the characteriza-
tion of their demethylase activity. One of the examples is
JMJD2C ⁄KDM4C, which was originally named “gene ampli-
fied in squamous cell carcinoma 1 (GASC1)”, because of its
amplification in esophageal cancer cells.(37) JMJD2C catalyzes
the removal of H3K9me2 ⁄3 and H3K36me2 ⁄3(38) and is also
overexpressed in osteosarcoma, medulloblastomas, breast can-
cer, primary mediastinal B-cell and Hodgkin lymphoma.(39–41)
Knockdown of JMJD2C inhibited proliferation of several
cancer cell lines, while forced expression could induce
transformed phenotypes in immortalized mammary epithelial
cells.(38,39)
We have also identified JMJD2C as an oncogene candidate by
our screens. To uncover the function of JMJD2C in oncogenesis,
we searched for the critical downstream target genes regulated
by JMJD2C and discovered MDM2 oncogene.(42) JMJD2C
increased the expression of MDM2, a negative regulator of
TP53. Increased levels of MDM2 correlated directly with
decreased TP53 product in the cells, suggesting that the MDM2
oncogene might mediate JMJD2C-related tumorigenesis.
Overexpression of JMJD2B ⁄KDM4B, another member
of KDM4 family, was also reported in bladder and lung
cancer.(43) Microarray analysis revealed that JMJD2B could
regulate the expression of genes involved in the cell cycle
pathway leading to oncogenesis, and that CDK6 (cyclin-
dependent kinase 6) was one of the important downstream
targets.(43) Although the exploration of the genomic targets
and cellular functions of KDM4 family members has just
started, this family is thought to be one of the feasible molecu-
lar targets for cancer therapy.
KDM5 family. Another example for early-described oncogene
product is PLU1 ⁄KDM5B demethylase. PLU1 was originally
identified in a screen for genes regulated by c-ErbB2
oncogene,(44) and is highly expressed in various types of
tumors such as breast, prostate, bladder and lung cancers.(44–46)
Increased expression of PLU1 caused proliferation in breast
cancer and depletion of PLU1 inhibited tumor growth in a
mouse mammary tumor model. KDM5 family of enzymes can
demethylate H3K4me3 ⁄me2, and function as transcriptional
repressors.(47) PLU1 regulates the expression of cellular genes
that control cell proliferation including BRCA1 tumor suppres-
sor, E2F1 and E2F2 genes.(46,47) Another KDM5 family
member, JARID1A ⁄KDM5A was also found overexpressed in
gastric and breast cancer.(48,49) Interestingly, KDM5 family
demethylases are proposed to play an important role in malig-
nant progression of cancer. This will be discussed in the
following section.
KDMs in the Process of Tumor Progression
Although accumulating evidence reveals the role of KDMs in
tumor initiation, a potential connection between KDMs and
tumor progression is yet to be fully investigated. In malignant
progression, it is a common event that patients who receive
extended chemotherapy respond well to it initially, but a
subpopulation of cancer cells becomes drug-resistant. One of
the KDMs, JARID1A ⁄KDM5A, has been shown to be associ-
ated with drug resistance in lung cancer cells.(50) Knockdown
of JARID1A reduced the number of drug resistant cells, but its
overexpression decreased the sensitivity of the whole popula-
tion to drug treatment.(50) This finding implicates that a distinct
chromatin status established by JARID1A is required for the
maintenance of the drug-tolerant subpopulation during tumor
progression.
We focused on another member of KDM5 family, PLU1 ⁄
KDM5B, since PLU1 is one of the oncogene candidates identi-
fied by our screens. In addition to the role in tumor initiation,
PLU1 was suggested to be associated with malignant progres-
sion of prostate cancer.(45) However, the mechanism by which
PLU1 contributed to tumor progression remained unclear. At
first, we examined whether ectopic expression of PLU1 could
affect the invasive potential of the cells.(51) Overexpression of
PLU1 enhanced the invasive potential of the weakly invasive
cells dependent on its demethylase activity (Fig. 3a,b). Among
the target genes transcriptionally repressed by PLU1, we
selected KAT5 ⁄TIP60 gene as a good candidate, since KAT5
was considered a tumor suppressor gene and reported to be
more frequently downregulated in advanced carcinoma.(52,53)
Our mechanistic investigations proved that the regulation of
KAT5 by PLU1 was responsible for the PLU1-induced cell
invasion. Moreover, we found that CD82 ⁄KAI1, which was
activated by KAT5, might be a candidate effector of cell
invasion promoted by PLU1 (Fig. 3c). KAI1 is a member of
the tetraspanin family of type III membrane proteins and a
metastasis suppressor gene for human malignancies including
(a) (b)
(c)
Fig. 3. Overexpression of PLU1 increased the invasive activity of the
cells. (a) A modified Boyden chamber assay was used to determine if
the cells invade through membranes coated with Matrigel. MCF10A
cells were infected with the control retrovirus or the retrovirus
expressing wild-type (WT) PLU1 or the mutant (Mut), and then inva-
sion assays were performed. Representative fields of invaded and
stained cells are shown. (b) PLU1 enhanced cell invasion dependent
on its demethylase activity. Cells that invaded through the membrane
to the lower surface were fixed, stained, and counted. P < 0.001
versus control. (c) Gene expression cascade underlying PLU1-induced
cell invasion. Mechanistic investigations suggested that PLU1 repressed
the downstream target gene KAT5 ⁄ Tip60 to lead to the downregula-
tion of CD82 ⁄ KAI1, a metastasis suppressor, thereby promoting the
invasive potential.
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prostate, breast, pancreatic and lung cancers.(54,55) Thus our
study demonstrated a novel role of KDM that could contribute
to cell invasion, one of the important features of cancer
aggressiveness.
Future Perspectives
Recently deregulation of histone methylation in cancer has
received increasing attention and consequently the list of
KMTs and KDMs associated with human cancers has been
steadily growing. However, in most cases, our understanding
of the molecular mechanisms that contribute to cancer devel-
opment is still quite limited. Many studies have evaluated the
expression of KMTs and KDMs and chromatin modifications
in cancer, but it is mostly unclear that these alterations are the
causative events or the effects of the disease itself. In the vari-
ous stages for malignant progression of tumors, we have only
recently become aware that KMTs and KDMs are implicated
in migration, invasion, epithelial-to-mesenchymal transition
(EMT) and drug resistance of cancer cells. To gain deeper
insights into the causes as well as the consequences of aberrant
histone methylation will definitely extend our comprehension
of cancer development. Furthermore, due to the reversibility of
histone methylation, the approaches that target KMTs and ⁄or
KDMs in cancer cells could be undoubtedly the next trend in
cancer therapies.
Acknowledgments
This work was supported in part by Grants-in-Aid for Scientific
Research from the Ministry of Education, Culture, Sports, Science and
Technology of Japan. The authors thank Ms Atsuko Odawara for
formatting the manuscript.
Disclosure Statement
The authors have no conflict of interest.
References
1 Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy.
Cell 2012; 150: 12–27.
2 You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same
coin? Cancer Cell 2012; 22: 9–20.
3 Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagen-
esis: past, present and future. Oncogene 2005; 24: 7656–72.
4 Suzuki T, Shen H, Akagi K et al. New genes involved in cancer identified
by retroviral tagging. Nat Genet 2002; 32: 166–74.
5 Touw IP, Erkeland SJ. Retroviral insertion mutagenesis in mice as a compar-
ative oncogenomics tool to identify disease genes in human leukemia. Mol
Ther 2007; 15: 13–19.
6 Mikkers H, Allen J, Knipscheer P et al. High-throughput retroviral tagging
to identify components of specific signaling pathways in cancer. Nat Genet
2002; 32: 153–9.
7 Lund AH, Turner G, Trubetskoy A et al. Genome-wide retroviral insertional
tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet
2002; 32: 160–5.
8 Suzuki T, Minehata K, Akagi K, Jenkins NA, Copeland NG. Tumor suppres-
sor gene identification using retroviral insertional mutagenesis in Blm-defi-
cient mice. EMBO J 2006; 25: 3422–31.
9 Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: ret-
roviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523–7.
10 Esteller M. Cancer epigenomics: DNA methylomes and histone-modification
maps. Nat Rev Genet 2007; 8: 286–98.
11 Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of
epigenetic genes. Hum Mol Genet 2007; 16(Spec No 1): R28–49.
12 Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and
clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp
Med Biol 2008; 615: 261–98.
13 Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: his-
tone demethylases at the center of cellular differentiation and disease. Genes
Dev 2008; 22: 1115–40.
14 Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and
molecular mechanisms of histone demethylases. Ann Rev Biochem 2010; 79:
155–79.
15 Kooistra SM, Helin K. Molecular mechanisms and potential functions of his-
tone demethylases. Nat Rev Genet 2012; 13: 297–311.
16 Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease
and inheritance. Nat Rev Genet 2012; 13: 343–57.
17 Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone
methylations in the human genome. Cell 2007; 129: 823–37.
18 Albert M, Helin K. Histone methyltransferases in cancer. Semin Dev Biol
2010; 21: 209–20.
19 Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads
to overexpression of histone methyltransferase EZH2 in cancer. Science
2008; 322: 1695–9.
20 Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering
EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germi-
nal-center origin. Nat Genet 2010; 42: 181–5.
21 Kondo Y, Shen L, Cheng AS et al. Gene silencing in cancer by histone H3
lysine 27 trimethylation independent of promoter DNA methylation. Nat
Genet 2008; 40: 741–50.
22 Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group pro-
tein EZH2 is involved in progression of prostate cancer. Nature 2002; 419:
624–9.
23 Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone meth-
yltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722–6.
24 Hoffmann I, Roatsch M, Schmitt ML et al. The role of histone demethylases
in cancer therapy. Mol Oncol 2012; 6: 683–703.
25 Ueda R, Suzuki T, Mino K et al. Identification of cell-active lysine specific
demethylase 1-selective inhibitors. J Am Chem Soc 2009; 131: 17536–7.
26 Kahl P, Gullotti L, Heukamp LC et al. Androgen receptor coactivators
lysine-specific histone demethylase 1 and four and a half LIM domain pro-
tein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66:
11341–7.
27 Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to
human carcinogenesis through chromatin regulation in various cancers. Int J
Cancer 2011; 128: 574–86.
28 Schulte JH, Lim S, Schramm A et al. Lysine-specific demethylase 1 is
strongly expressed in poorly differentiated neuroblastoma: implications for
therapy. Cancer Res 2009; 69: 2065–71.
29 Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex
and targets the metastasis programs in breast cancer. Cell 2009; 138: 660–72.
30 Agger K, Cloos PA, Christensen J et al. UTX and JMJD3 are histone
H3K27 demethylases involved in HOX gene regulation and development.
Nature 2007; 449: 731–4.
31 Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal
carcinoma reveals inactivation of histone modifying genes. Nature 2010;
463: 360–3.
32 van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the
histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009;
41: 521–3.
33 Jankowska AM, Makishima H, Tiu RV et al. Mutational spectrum analysis
of chronic myelomonocytic leukemia includes genes associated with epige-
netic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932–41.
34 Agger K, Cloos PA, Rudkjaer L et al. The H3K27me3 demethylase JMJD3
contributes to the activation of the INK4A-ARF locus in response to onco-
gene- and stress-induced senescence. Genes Dev 2009; 23: 1171–6.
35 Barradas M, Anderton E, Acosta JC et al. Histone demethylase JMJD3
contributes to epigenetic control of INK4a ⁄ ARF by oncogenic RAS. Genes
Dev 2009; 23: 1177–82.
36 Terashima M, Ishimura A, Yoshida M, Suzuki Y, Sugano S, Suzuki T. The
tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone
demethylase. Biochem Biophys Res Commun 2010; 399: 238–44.
37 Yang ZQ, Imoto I, Fukuda Y et al. Identification of a novel gene, GASC1,
within an amplicon at 9p23-24 frequently detected in esophageal cancer cell
lines. Cancer Res 2000; 60: 4735–9.
38 Cloos PA, Christensen J, Agger K et al. The putative oncogene GASC1
demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006;
442: 307–11.
39 Liu G, Bollig-Fischer A, Kreike B et al. Genomic amplification and onco-
genic properties of the GASC1 histone demethylase gene in breast cancer.
Oncogene 2009; 28: 4491–500.
40 Northcott PA, Nakahara Y, Wu X et al. Multiple recurrent genetic events
converge on control of histone lysine methylation in medulloblastoma. Nat
Genet 2009; 41: 465–72.
Suzuki et al. Cancer Sci | July 2013 | vol. 104 | no. 7 | 799
© 2013 Japanese Cancer Association
41 Rui L, Emre NC, Kruhlak MJ et al. Cooperative epigenetic modulation by
cancer amplicon genes. Cancer Cell 2010; 18: 590–605.
42 Ishimura A, Terashima M, Kimura H et al. Jmjd2c histone demethylase
enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun
2009; 389: 366–71.
43 Toyokawa G, Cho HS, Iwai Y et al. The histone demethylase JMJD2B plays
an essential role in human carcinogenesis through positive regulation of
cyclin-dependent kinase 6. Cancer Prev Res (Phila) 2011; 4: 2051–61.
44 Lu PJ, Sundquist K, Baeckstrom D et al. A novel gene (PLU-1) containing
highly conserved putative DNA ⁄ chromatin binding motifs is specifically
up-regulated in breast cancer. J Biol Chem 1999; 274: 15633–45.
45 Xiang Y, Zhu Z, Han G et al. JARID1B is a histone H3 lysine 4 demethy-
lase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007; 104:
19226–31.
46 Hayami S, Yoshimatsu M, Veerakumarasivam A et al. Overexpression of
the JmjC histone demethylase KDM5B in human carcinogenesis: involve-
ment in the proliferation of cancer cells through the E2F ⁄ RB pathway. Mol
Cancer 2010; 9: 59.
47 Yamane K, Tateishi K, Klose RJ et al. PLU-1 is an H3K4 demethylase
involved in transcriptional repression and breast cancer cell proliferation.
Mol Cell 2007; 25: 801–12.
48 Zeng J, Ge Z, Wang L et al. The histone demethylase RBP2 Is overexpres-
sed in gastric cancer and its inhibition triggers senescence of cancer cells.
Gastroenterology 2010; 138: 981–92.
49 Hou J, Wu J, Dombkowski A et al. Genomic amplification and a role in
drug-resistance for the KDM5A histone demethylase in breast cancer. Am J
Transl Res 2012; 4: 247–56.
50 Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-toler-
ant state in cancer cell subpopulations. Cell 2010; 141: 69–80.
51 Yoshida M, Ishimura A, Terashima M et al. PLU1 histone demethylase
decreases the expression of KAT5 and enhances the invasive activity of the
cells. Biochem J 2011; 437: 555–64.
52 Gorrini C, Squatrito M, Luise C et al. Tip60 is a haplo-insufficient tumour
suppressor required for an oncogene-induced DNA damage response. Nature
2007; 448: 1063–7.
53 Me LL, Vidal F, Gallardo D et al. New p53 related genes in human tumors:
significant downregulation in colon and lung carcinomas. Oncol Rep 2006;
16: 603–8.
54 Dong JT, Lamb PW, Rinker-Schaeffer CW et al. KAI1, a metastasis
suppressor gene for prostate cancer on human chromosome 11p11.2. Science
1995; 268: 884–6.
55 Miranti CK. Controlling cell surface dynamics and signaling: how CD82
⁄ KAI1 suppresses metastasis. Cell Signal 2009; 21: 196–211.
56 Mallette FA, Richard S. JMJD2A promotes cellular transformation by block-
ing cellular senescence through transcriptional repression of the tumor sup-
pressor CHD5. Cell Rep 2012; 2: 1233–43.
57 Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expres-
sion profiles are associated with pathological and clinical outcomes in human
breast cancer. Anticancer Res 2011; 31: 4115–25.
58 Yang J, Jubb AM, Pike L et al. The histone demethylase JMJD2B is regu-
lated by estrogen receptor alpha and hypoxia, and is a key mediator of estro-
gen induced growth. Cancer Res 2010; 70: 6456–66.
59 Tzatsos A, Paskaleva P, Ferrari F et al. KDM2B promotes pancreatic cancer
via Polycomb-dependent and -independent transcriptional programs. J Clin
Invest 2013; 123: 727–39.
60 He J, Nguyen AT, Zhang Y. KDM2b ⁄ JHDM1b, an H3K36me2-specific
demethylase, is required for initiation and maintenance of acute myeloid
leukemia. Blood 2011; 117: 3869–80.
61 Frescas D, Guardavaccaro D, Bassermann F, Koyama-Nasu R, Pagano M.
JHDM1B ⁄ FBXL10 is a nucleolar protein that represses transcription of ribo-
somal RNA genes. Nature 2007; 450: 309–13.
62 Uemura M, Yamamoto H, Takemasa I et al. Jumonji domain containing 1A
is a novel prognostic marker for colorectal cancer: in vivo identification from
hypoxic tumor cells. Clin Cancer Res 2010; 16: 4636–46.
63 Guo X, Shi M, Sun L et al. The expression of histone demethylase JMJD1A
in renal cell carcinoma. Neoplasma 2011; 58: 153–7.
64 Wang GG, Song J, Wang Z et al. Haematopoietic malignancies caused
by dysregulation of a chromatin-binding PHD finger. Nature 2009; 459:
847–51.
65 Roesch A, Becker B, Meyer S et al. Retinoblastoma-binding protein
2-homolog 1: a retinoblastoma-binding protein downregulated in malignant
melanomas. Mod Pathol 2005; 18: 1249–57.
66 Bjorkman M, Ostling P, Harma V et al. Systematic knockdown of epigenetic
enzymes identifies a novel histone demethylase PHF8 overexpressed in pros-
tate cancer with an impact on cell proliferation, migration and invasion.
Oncogene 2012; 31: 3444–56.
800 doi: 10.1111/cas.12169
© 2013 Japanese Cancer Association
